Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in HFrEF (Empire HF)
NCT03198585Phase 2Completed
- Start
- Jun 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Empagliflozin 10 mg with Placebo (2 arms). Primary endpoint: Change in plasma concentrations of N-terminal pro-brain natriuretic peptide at 90 days. Started Jun 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03198585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198585.